home / stock / aplif / aplif news

APLIF News and Press, Appili Therapeutics Inc

Stock Information
Company Name: Appili Therapeutics Inc
Stock Symbol: APLIF
Market: OTC
Website: appilitherapeutics.com
Menu
APLIF APLIF Quote APLIF Short APLIF News APLIF Articles APLIF Message Board
Get APLIF Alerts

News, Short Squeeze, Breakout and More Instantly...
APLIF - Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug...
APLIF - Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

  US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOB...

APLIF - Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on ...

APLIF - Appili Therapeutics Inc. GAAP EPS of -$0.01

2025-11-14 11:26:57 ET More on Appili Therapeutics Inc. Seeking Alpha’s Quant Rating on Appili Therapeutics Inc. Financial information for Appili Therapeutics Inc. Read the full article on Seeking Alpha For further details see: Appili Therapeutics ...
APLIF - Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth HALIFAX, Nova Scotia, Nov. ...

APLIF - Appili Therapeutics Announces Proposed Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company ...

APLIF - Appili Therapeutics to Attend BARDA Innovation Symposium 2025

HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced Research and Development Authority (BARDA) Innovation Symposium on Nove...
APLIF - Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional U.S. government funding proposals HALIFAX, Nova Scotia, Oct. 01, 2025 (GLOBE NEWSWIRE...

APLIF - Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the re...

APLIF - Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference

HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus,...
Next 10